Henlius Biotech’s Hanbeitai Approved for Hepatocellular Carcinoma
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving a fourth indication approval from the...
Antengene’s Xpovio Receives Taiwan FDA Approval for Multiple Indications
China-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced receiving market approval from the Taiwan...
AIM Vaccine Receives CDE Approval for Serum-Free Rabies Vaccine Trial
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving clinical trial approval from the...
Rici Healthcare to Acquire Unicorn II Holdings for RMB 180M
China-based Rici Healthcare Holdings Limited (HKG: 1526), also known as Rich Healthcare, is set to...
Roche Reports Q3 Sales Growth, Hit by COVID-19 Product Decline
Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2022 financial report last week, showing...
Ambrx Biopharma Halts Development of HER2 ADC ARX788, Cuts Workforce
US-based, China-owned biotech Ambrx Biopharma Inc. (NYSE: AMAM) has announced plans to end the development...
Sinopharm’s Wuhan Institute Isolates Monkeypox Strains, Begins Vaccine Research
China’s Wuhan Institute of Biological Products, a research affiliate of Sinopharm’s China National Biotech Group...
CATUG Biotechnology Partners with Duoning to Advance mRNA Industrialization
China-based CATUG Biotechnology (Suzhou) Co., Ltd has entered into a partnership with compatriot firm Shanghai...
Fujian Procurement Center Announces VBP for Cardiac and Laparoscopic Medical Consumables
The Fujian drug and device joint procurement center has released two separate notifications regarding the...
NMPA Releases 61st Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 61st batch of reference drugs for...
Betta Pharmaceuticals’ BPI-460372 Accepted for Clinical Trial Review by NMPA
China’s Betta Pharmaceuticals (SHE: 300558) has announced that its clinical trial filing for the Category...
Frontier Biotechnologies Secures Approval for HIV Therapy Alfusid
Nanjing-based Frontier Biotechnologies Inc. has announced that its supplementary market filing for Alfusid (albuvirtide), China’s...
Hengrui’s Camrelizumab and Akeso’s AK112 Set to Receive Breakthrough Designation in China
The Center for Drug Evaluation (CDE) website indicates that China-based Jiangsu Hengrui Medicine Co., Ltd’s...
China Approves GSK’s Juluca for HIV-1 Infection
The National Medical Products Administration (NMPA) has approved the market application for GlaxoSmithKline’s (GSK, NYSE:...
Hengrui Medicine Files for Dalpiciclib as Initial Therapy for Breast Cancer
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced a supplementary market filing for...
HitGen Partners with C4X Discovery to Identify Novel Inflammatory Disease Treatments
China-based HitGen Inc. (SHA: 688222) has announced a partnership with UK-headquartered C4X Discovery Holdings plc...
Abbott Reports Q3 Sales Growth, Raises Full-Year EPS Guidance
With the Q3 2022 reporting season underway, US-based medtech giant Abbott (NYSE: ABT) released its...
Shaanxi Releases Notice for Inter-Provincial Orthodontic Brackets VBP
The Shaanxi Public Resources Trading Center has released the “Inter-provincial Alliance (regions, Corps) Orthodontic Brackets...
Hainan Poly Pharm’s Generic Ganciclovir Approved in Sweden for CMV Retinitis
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving technical review approval from...
Bio-Thera’s BAT1806 Biosimilar Accepted for Review by European Medicine Agency
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that a Biologic License Application (BLA) for...